Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Researchers ID Best Source of Stem Cells to Block Diabetic Blindness

By Drug Discovery Trends Editor | June 24, 2015

University of Virginia School of Medicine researchers have taken a significant step forward in their efforts to use stem cells to block vision loss caused by diabetic retinopathy, a condition that affects millions of people with diabetes. The researchers have evaluated the best potential sources for adult stem cells to be used for that purpose, determining that cells taken from donors who do not suffer diabetes likely will be more effective than cells taken from patients’ own bodies.
 
The work is a critical step toward the goal of injecting stem cells into patients’ eyes to stop or even reverse the vision loss. The findings also establish a crucial framework for evaluating stem cells to be used in potential future treatments for diabetic retinopathy.
 
“It answers a vital question: If we’re going to carry this therapy forward into clinical trials, where are we going to get the best bang for the buck?” said UVA researcher and ophthalmologist Paul Yates, MD, PhD. “The answer seems to be, probably, taking cells from patients who aren’t diabetic. Because the diabetic stem cells don’t seem to work quite as well. And that’s not terribly surprising, because we already know that this cell type is damaged by diabetes.”
 
Growing Problem of Diabetic Retinopathy
 
The researchers hope to use fat-derived stem cells – harvested during liposuction procedures — to stop the vascular degeneration that leads to blindness in patients with diabetic retinopathy. To do that, they must understand the best source of those cells, and UVA’s new research provides those important answers. “We now know what to look for when we harvest a patient’s cells, because we know what distinguishes good quality cells from poor quality,” said researcher Shayn M. Peirce, PhD, of the UVA Department of Biomedical Engineering. “We almost have a screen to determine quality control. We’re essentially establishing quality-control criteria by understanding what works and why.”
 
New and better treatments for diabetic retinopathy are needed desperately, the researchers noted, both because of the growing number of people with the condition and because of the limited effectiveness of existing treatments. More than 100 million people are estimated to suffer from diabetic retinopathy and related conditions; current treatments either destroy much of the retina with a laser or require patients to receive injections directly into their eyeball as often as monthly for the rest of their lives.
 
“There’s huge room for improvement on the standard of care, and the number of patients in this demographic is increasing by the day, dramatically, so the need is only going up,” Peirce said. “So I think there are three pieces working together – UVA’s strengths in this area, the FDA’s encouragement [of stem cell research in the eye] and the clinical realities – to drive this cell-based therapy toward the clinic.”
 
While much more work needs to be done, if all goes well, the researchers hope to begin clinical trials in humans within the next few years. “This is not science fiction at all,” Yates said. “The idea that you can take cells from somewhere else and inject them into the eye to treat disease is here today.”
 
Source: University of Virginia School of Medicine

Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50